Gavorestat is under clinical development by Applied Therapeutics and currently in Phase III for Unspecified Metabolic Disorders. According to GlobalData, Phase III drugs for Unspecified Metabolic Disorders does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Gavorestat LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gavorestat overview
Govorestat (AT-007) is under development for the treatment of galactosemia in both adult and pediatric patients, Charcot-Marie-tooth disease, sorbitol dehydrogenase deficiency (SORD Deficiency) and PMM2-CDG, formerly known as congenital disorder of glycosylation type 1a. The drug candidate is administered through oral route in the form of suspension. It acts by targeting aldose reductase.
Applied Therapeutics overview
Applied Therapeutics is a clinical-stage biopharmaceutical company that develops novel drug candidates against validated molecular targets. The company’s pipeline products include govorestat (AT-001), an investigational novel aldose reductase inhibitor that targets diabetic peripheral neuropathy and diabetic cardiomyopathy (DbCM); govorestat for sorbitol dehydrogenase (SORD) deficiency and phosphomannomutase 2 deficiency (PMM2-CDG); and AT-003 aldose reductase inhibitor (ARI) treats diabetic retinopathy. Applied Therapeutics is headquartered in New York, the US.
For a complete picture of Gavorestat’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
